PCRX Q2 2019 Earnings — Pacira BioSciences, Inc. Revenue & Financial Results | Market Cap Arena

PCRXPacira BioSciences, Inc.

$969M

Q2 2019 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$103M+22.0% YoY

Gross Profit

$77M75.4% margin

Operating Income

$5M5.1% margin

Net Income

$3M2.7% margin

EPS (Diluted)

$0.06

QoQ Revenue Growth

+12.4%

Cash Flow

Operating Cash Flow

$23M

Free Cash Flow

$21M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$788M

Total Liabilities

$446M

Stockholders' Equity

$342M

Cash & Equivalents

$60M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$103M	$84M	+22.0%
Gross Profit	$77M	$63M	+22.5%
Operating Income	$5M	$7M	-19.4%
Net Income	$3M	$3M	+6.5%

Revenue Segments

Product

$102M99%

Royalty

$780,0001%